Oh they are so transparent. It doesn't matter what they say because it so obvious that they are just a mouthpiece for the some short position. LOL
Third time in the last three days that a negative article from Zach's has been highlighted on this site. Seems that some short or fund is trying to poison the atmosphere here.
So basically the Chairman of Board owns over 640,000 REGN shares ,,,yesterday he cashed out 300,000 plus stock options and kept 150,000 shares with a purchase at $351.. The half he sold was for tax purposes. Good sign ; he didnt sell all 300,000 options on cash out.
They did the same thing in May, then in June, and now again in August. LOL Just Google, you will see. They have no understanding of Biotech.. They should be embarrassed by their ignorance, but doesn't seem to keep them from publishing the same worthless information. Kind of destroys their brand. Thats whats more surprising to me, they do good in other areas, but continue to try to comment on an area they clearly have no understanding of, BIOTECH.
Look at the history of performance after a split. Stocks rarely do well after a split. Apple is the notable exception but there are many more examples of no growth after a split
Wake up. That will never happen! Sny has disclosed iys intention top by 20-30% of regn. It has set a floor in regn's stock prioce in the $280s based on recent purchases. Imho i believe that sny will buy regn at $400 ps.
Sentiment: Strong Buy
A harbinger of ominousness. Do you recall the REGN big slide in during the middle of the day? This is something indicative of this.
Sorry but nothing is happening in the short term. I wish it would but its just not going to happen anytime soon. Read the public disclosures. Bayer and Sanofi both are capped as to how much stock they can buy. Sanofi is up to 30%. No deal is going to happen unless REGN and Leonard want it to happen. Agreement runs for a few more years. Slow and steady! Good luck to all!
Sanofi may also buy out MNKD who they just partnered with for their recently approved fast acting inhaled insulin drug “Afrezza”, Now, given the potential blockbuster potential of this drug you would think that of all people, Regeneron employees and stock holders might understand what may lay ahead. 385 million diabetics worldwide but 3 times the market for pre-diabetics, which is in play! I would think given the low price currently for MNKD, it would be worth investigating. Remember, well, how could we forget that when Regeneron, got approved it basically went nowhere, then just 4 months after FDA approval, initial sell in figures came in and you know what happened. Once sell n revenues are reported from the field that's all we need to know!
sny will buy regeneron thats why there buying up shares. and next up sanofi is mannkind corp